Janelidze S, Hertze J, Nägga K, Nilsson K, Nilsson C, Swedish BioFINDER Study Group, Wennström M, van Westen D, Blennow K, Zetterberg H, Hansson O. Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype. Neurobiol Aging. 2017 Mar;51:104-112. Epub 2016 Dec 5 PubMed.
AlzBiomarker Database
Meta-Analysis
- AD vs CTRL : Aβ40 (CSF)
- CTRL vs AD : Aβ40 (CSF)
- FTD vs AD : Aβ40 (CSF)
- MCI-AD vs MCI-Stable : Aβ40 (CSF)
- AD vs CTRL : Aβ42 (CSF)
- CTRL vs AD : Aβ42 (CSF)
- FTD vs AD : Aβ42 (CSF)
- MCI-AD vs MCI-Stable : Aβ42 (CSF)
- AD vs CTRL : albumin ratio (CSF)
- CTRL vs AD : albumin ratio (CSF)
- FTD vs AD : albumin ratio (CSF)
- MCI-AD vs MCI-Stable : albumin ratio (CSF/Blood)
- VaD vs AD : albumin ratio (CSF)
Curated Study Data
Biomarker (Source) |
Cohort (N) |
Measurement Mean ± SD |
Method; Assay Name; Manufacturer |
Diagnostic Criteria |
---|---|---|---|---|
Aβ40 (CSF) |
AD (75) |
3899 ± 1376 pg/mL |
ELISA; Euroimmun; Euroimmun AG |
McKhann et al., 1984; 1986 |
Aβ40 (CSF) |
CTRL- CNC (65) |
5241 ± 1487 pg/mL |
ELISA; Euroimmun; Euroimmun AG |
|
Aβ40 (CSF) |
FTD (41) |
4530 ± 1536 pg/mL |
ELISA; Euroimmun; Euroimmun AG |
Neary et al., 1998 |
Aβ40 (CSF) |
MCI-AD (35) |
4219 ± 1327 pg/mL |
ELISA; Euroimmun; Euroimmun AG |
Petersen, 2004; McKhann et al., 1984 |
Aβ40 (CSF) |
MCI-Stable (61) |
3786 ± 1360 pg/mL |
ELISA; Euroimmun; Euroimmun AG |
Petersen, 2004 |
Aβ42 (CSF) |
AD (75) |
259.7 ± 105 pg/mL |
ELISA; Euroimmun; Euroimmun AG |
McKhann et al., 1984; 1986 |
Aβ42 (CSF) |
CTRL- CNC (65) |
675.2 ± 289.8 pg/mL |
ELISA; Euroimmun; Euroimmun AG |
|
Aβ42 (CSF) |
FTD (41) |
682.9 ± 290.5 pg/mL |
ELISA; Euroimmun; Euroimmun AG |
Neary et al., 1998 |
Aβ42 (CSF) |
MCI-AD (35) |
314.5 ± 78.9 pg/mL |
ELISA; Euroimmun; Euroimmun AG |
Petersen, 2004; McKhann et al., 1984 |
Aβ42 (CSF) |
MCI-Stable (61) |
478.9 ± 195 pg/mL |
ELISA; Euroimmun; Euroimmun AG |
Petersen, 2004 |
albumin ratio (CSF/Blood) |
AD (75) |
7.6 ± 3.4 ratio |
Turbidimetry; Roche Cobas Analyzer; Roche |
McKhann et al., 1984; 1986 |
albumin ratio (CSF/Blood) |
CTRL- CNC (65) |
6.3 ± 2.9 ratio |
Turbidimetry; Roche Cobas Analyzer; Roche |
|
albumin ratio (CSF/Blood) |
FTD (41) |
8.6 ± 5.5 ratio |
Turbidimetry; Roche Cobas Analyzer; Roche |
Neary et al., 1998 |
albumin ratio (CSF/Blood) |
MCI-AD (35) |
7.1 ± 3.3 ratio |
Turbidimetry; Roche Cobas Analyzer; Roche |
Petersen, 2004; McKhann et al., 1984 |
albumin ratio (CSF/Blood) |
MCI-Stable (61) |
6.3 ± 2.5 ratio |
Turbidimetry; Roche Cobas Analyzer; Roche |
Petersen, 2004 |
albumin ratio (CSF/Blood) |
VaD (28) |
8.7 ± 3.7 ratio |
Turbidimetry; Roche Cobas Analyzer; Roche |
Román et al., 1993; 1986 |
Recommends
Please login to recommend the paper.
This paper appears in the following:
AlzBiomarker
- AD vs CTRL : Aβ40 (CSF)
- CTRL vs AD : Aβ40 (CSF)
- FTD vs AD : Aβ40 (CSF)
- MCI-AD vs MCI-Stable : Aβ40 (CSF)
- AD vs CTRL : Aβ42 (CSF)
- CTRL vs AD : Aβ42 (CSF)
- FTD vs AD : Aβ42 (CSF)
- MCI-AD vs MCI-Stable : Aβ42 (CSF)
- AD vs CTRL : albumin ratio (CSF)
- CTRL vs AD : albumin ratio (CSF)
- FTD vs AD : albumin ratio (CSF)
- MCI-AD vs MCI-Stable : albumin ratio (CSF/Blood)
- VaD vs AD : albumin ratio (CSF)
Comments
No Available Comments
Make a Comment
To make a comment you must login or register.